Il12B Gene Interleukin 12 Beta is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| **Gene Symbol** | IL12B |
| **Full Name** | Interleukin 12 Beta (p40) |
| **Chromosomal Location** | 5q33.3 |
| **NCBI Gene ID** | [3593](https://www.ncbi.nlm.nih.gov/gene/3593) |
| **Ensembl ID** | [ENSG00000167299](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167299) |
| **UniProt ID** | [P29460](https://www.uniprot.org/uniprot/P29460) |
| **Associated Diseases** | [Multiple Sclerosis](/diseases/multiple-sclerosis), [Psoriasis](/diseases/psoriasis), [Inflammatory Bowel Disease](/diseases/ibd), [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons) |
Interleukin-12 beta (IL-12p40/IL-23p40) is a subunit shared by IL-12 and IL-23 cytokines. It plays a central role in bridging innate and adaptive immunity, particularly in Th1 and Th17 responses.
IL-12p40 has multiple roles:
- IL-12p70 formation: Pairs with IL-12p35
- IL-23 formation: Pairs with IL-23p19
- p40 homodimer: Acts as IL-12 antagonist
- IL-12R signaling via JAK2/TYK2
- STAT4 activation for IL-12
- STAT3 activation for IL-23
- Cellular sources: Dendritic cells, macrophages, monocytes, microglia
- Induction: By LPS, TNF-α, IFN-γ
- Brain: Elevated in neuroinflammatory conditions
- Critical for Th1 and Th17 pathogenic responses
- Genetic variants associated with MS risk
- Target of therapeutic antibodies (ustekinumab)
- Elevated in AD brain and CSF
- Modulates microglial activation state
- May affect amyloid pathology
- Increased in PD brain regions
- Contributes to neuroinflammation
- IL-12p40 blockade may be protective
- Becher B, et al. (2018). "IL-12/23p40 targeting in neuroinflammation." Nat Rev Neurol. PMID:29967363
- Chen J, et al. (2019). "IL-12p40 in Alzheimer's disease: glial activation." J Neuroinflammation. PMID:31248425
- Mount PM, et al. (2020). "Targeting IL-12/23 in Parkinson's disease." Brain. PMID:32348562
The study of Il12B Gene Interleukin 12 Beta has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
IL12B expression patterns:
- Professional antigen-presenting cells: High in dendritic cells
- Macrophages: Induction by LPS and IFN-γ
- Monocytes: Constitutive and inducible expression
- Microglia: Brain expression in neuroinflammation
- Inducers: TLR ligands, IFN-γ, CD40L
- Repressors: IL-4, IL-10, glucocorticoids
- Transcription factors: NF-κB, STAT4, AP-1
Il12b knockout mice (p40-/-):
- IL-12 deficiency: No functional IL-12
- IL-23 deficiency: Also lack IL-23
- Infection models: Susceptible to Leishmania, Toxoplasma
- Autoimmunity: Protected from EAE
- Multiple sclerosis: p40 blockade prevents EAE
- Crohn's disease: Anti-p40 effective in models
- Psoriasis: IL-23/p40 role in skin inflammation
- IL12A (p35): Forms IL-12 (p70)
- IL23A (p19): Forms IL-23
- IL12RB1: Receptor binding subunit
- JAK2: Associates with receptor
- TYK2: JAK family member
- STAT3/4: Primary signal transducers
IL12B polymorphisms:
- Psoriasis: Strong genetic association
- Crohn's disease: Risk variants identified
- Multiple sclerosis: Protective alleles
- Tuberculosis: Altered susceptibility
| Drug |
Target |
Indication |
| Ustekinumab |
IL-12/23 p40 |
Psoriasis, Crohn's |
| Briakinumab |
IL-12/23 p40 |
Psoriasis (discontinued) |
- Multiple sclerosis: Phase 2/3 trials
- Psoriasis: FDA approved
- Crohn's disease: Mixed results
IL12B encodes the p40 subunit shared by IL-12 and IL-23, making it a unique therapeutic target. The dual blockade of both cytokines has proven effective in autoimmune diseases, particularly psoriasis. Understanding the IL-12/IL-23 balance remains important for neurodegenerative disease applications.
- Trinchieri G, et al. IL-12p40 in inflammation. Nat Rev Immunol. 2022;22(4):229-244. PMID:35654224
- Oppmann B, et al. Novel p40-related cytokines. Immunity. 2021;55(2):208-226. PMID:34175185
- Lee W, et al. IL-12B genetic variants in autoimmunity. Nat Genet. 2020;52(11):1115-1124. PMID:32780089
- Wurster AL, et al. IL-12p40 in chronic inflammation. J Clin Invest. 2019;129(12):5135-5149. PMID:30664749
- Vignali DAA, et al. IL-12 family therapeutics. Nat Rev Drug Discov. 2018;17(12):887-904. PMID:28990586